Rosacea, reactive oxygen species, and azelaic acid

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 1, 2009, Pages 26-30

  Jones, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; METRONIDAZOLE; REACTIVE OXYGEN METABOLITE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; HUMAN; NEUTROPHIL; PATHOPHYSIOLOGY; ROSACEA; SKIN INFLAMMATION;

EID: 77953420470     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
2. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001;18:237-243.
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-587.
4. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;74(Suppl 3):21-27.
5. Millikan L. Rosacea as an inflammatory disorder: a unifying theory. Cutis. 2004;73(Supp l1):5-8.
6. Scheinfeld NS. Rosacea. Skinmed. 2006;5:191-194.
7. Murphy G. Ultraviolet light and rosacea. Cutis. 2004;74(suppl):13-16.
8. Ramelet AA, Perroulaz G. Rosacea: histopathologic study of 75 cases. Ann Dermatol Venereol. 1998;115:801-806 [article in French].
9. Powell C. Rosacea and the pilosebaceous follicle. Cutis. 2004;74(Suppl 3):9-12,32-34.
10. Odom RB. The subtypes of rosacea: implications for treatment. Cutis. 2004;74(Suppl 3):5-8,32-34.
11. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
12. Hirakawa S, Fujii S, Kajiya K, et al. Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage. Blood. 2005;105:2392-2399.
13. Jones D. Reactive oxygen species and rosacea. Cutis. 2004;74 (Suppl 3):17-20.
14. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98(7):1667-1675.
15. Guzman-Sanchez DA, McMichael A. topical uses of vitamin C: how ascorbic acid is being used in dermatology. Skin & Aging. 2006;14:52-59.
16. Sundaram C, Köster W, Schallreuter KU. The effect of UV radiation and sun blockers on free radical defense in human and guinea pig epidermis. Arch Dermatol Res. 1990;282:526-531.
17. Oztas MO, Balk M, Ogus E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28(2):188-192.
18. Januszewski AS, Alderson NL, Jenkins AJ, et al. Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res. 2005;46:1440-1449.
19. Kawai Y, Kato Y, Fujii H, et al. Immunochemical detection of a novel lysine adduct using an antibody to linoleic acid hydroperoxoide-modified protein. J Lipid Res. 2003;44:1124-1131.
20. Akamatsu H, Niwa Y, Matsunaga K. Effect of palmitic acid on neutrophil functions in vitro. Int J Dermatol. 2001;40:640-643.
21. Zheng Y, Niyonsaba F, Ushio H, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Brit J Dermatol. 2007;157(6):1124-1131.
22. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980.
23. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341(24):1817-1828.
24. Yazici AC, Tamer L, Ikizoglu G, et al. GSTM1 and GSTT1 null genotypes as possible heritable factors of rosacea. Photodermatol Photoimmunol Photomed. 2006;22: 208-210.
25. Humbert P. Topical vitamin C in the treatment of photoaged skin. Eur J Dermatol. 2001;11(2):163-174.
26. Passi S, Picardo M, De Luca C, et al. Scavenging activity of azelaic acid on hydroxyl radicals "in vitro." Free Radic Res Commun. 1991;11:329-338.
27. Passi S, Picardo M, Zompetta C, et al. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun. 1991;15:17-28.
28. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449-453.
29. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects on metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermtol Res. 1990;282:449-454.
30. Zip C. An update on the role of topical metronidazole in rosacea. Skin Therapy Lett. 2006:11:1-4.
31. Wolf JE, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(Suppl 4):3-11.
32. Bikowski JB. Subantimicrobial-dose doxycycline for acne and rosacea. Skinmed. 2003;2:234-245.
33. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
34. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;137(7): 884-885.
35. Niren NM, Torok HM. The nicomide improvement in clinical outcomes study (NICOS): results of an 8-week trial. Cutis. 2006;77(Suppl 1):17-28.
36. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
37. Fitton A, Goa KL. Azelaic acid. A review of pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41:780-798.
38. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects on metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermtol Res. 1990;282:449-454.
39. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6 Pt. 1):961-965.
40. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450.